Rifampin
As of the edition of 20 October 2026, Rifampin is a small molecule: marketed, first approved in 1968 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Small molecule
- Brand name
- Rifadin
- First approved
- 1 June 1968 (ES)
- Approvals on record
- 12 in 6 regions
- Holder of the most recent approval
- Sanofi; 4 holders in all
- Registered trials
- 344, 19 stopped early
- Disease areas
- Infections; Lungs and airways; Immune system; Cancer; Urinary and reproductive; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 25 | 18 | 4 | 1 |
| Phase 1 | 228 | 191 | 13 | 12 |
| Phase 2 | 37 | 25 | 5 | 3 |
| Phase 3 | 27 | 16 | 7 | 1 |
| Phase 4 | 27 | 15 | 4 | 2 |
| All trials | 344 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Applicant and Lead sponsor of trials | 1975 to now |
| Bausch Health | Acquired holder | 1977 to now |
| Novartis | Later holder and Lead sponsor of trials | 2007 to now |
| Oxford Pharmaceuticals | Acquired holder | 2016 to now |